TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject (or his or her legally appointed and authorized representative) will sign and date an informed consent form (ICF).~* Willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, contraceptive guidelines, and other study procedures.~* Confirmed diagnosis of CF and homozygous for the F508del-CFTR mutation~* Forced Expiratory Volume in one second/forced vital capacity (FEV1) ≥40% of predicted normal for age, sex, and height~Exclusion Criteria:~* Presence of moderate or severe hepatic impairment (Child-Pugh Class B or C)~* Subjects currently receiving invasive mechanical ventilation~* Known history of alcohol or drug abuse in the past year~* Clinically significant abnormal laboratory values during screening~* Pregnant or nursing females~* Female subjects and female partners of male subjects who plan to become pregnant during Treatment Period or within 90 days following the last dose of study drug~* History of solid organ or hematological transplantation~* Ongoing or prior participation in an investigational drug study within 30 days of screening~* Current use of commercial LUM/IVA combination therapy

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: activated smart device alerts and feedback (Type: EXPERIMENTAL): LUM/IVA: LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
- Arm B: de-activated smart device alerts/feedback features (Type: EXPERIMENTAL): LUM/IVA: LUM 400 mg q12h/IVA 250 mg q12h through Week 48.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Acute myeloid leukemia (AML): high risk CR1~* Acute lymphocytic leukemia (ALL): high risk CR1 \[t(9;22), t (1:19), t(4;11) or other MLL rearrangements\] or \> 1 cycle to obtain CR; CR2+. All patients must be in CR as defined by hematological recovery, AND \<5% blasts by light microscopy within the bone marrow with a cellularity of ≥15%.~* Chronic myelogenous leukemia (CML) excluding refractory blast crisis. To be eligible in first chronic phase (CP1) patient must have failed or be intolerant to imatinib mesylate.~* Myelodysplasia (MDS) IPSS Int-2 or High risk (i.e. RAEB, RAEBt) or refractory anemia with severe pancytopenia or high risk cytogenetics.~* Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma or follicular lymphoma that have progressed after at least two prior therapies. Patients with bulky disease (nodal mass greater than 5 cm).~* Lymphoplasmacytic lymphoma, mantle-cell lymphoma, prolymphocytic leukemia are eligible after initial therapy in CR1+ or PR1+.~* Large cell NHL \> CR2/\> PR2. Patients in CR2/PR2 with initial short remission (\<6 months) are eligible.~* Lymphoblastic lymphoma.~* Multiple myeloma beyond PR2.~* Karnofsky performance status (PS) 90-100% (adults)~* Lansky PS 50-100% (children)~* Acceptable organ function~Exclusion Criteria:~* Active infection at time of transplantation~* History of HIV infection~* Pregnant or breast feeding.~* Chemotherapy refractory large cell and high grade NHL (ie progressive disease after \> 2 salvage regimens)~* Extensive prior therapy including \> 12 months alkylator therapy or \> 6 months alkylator therapy with extensive radiation.~* Diffuse myelofibrosis of BM (bone marrow) (any severity) regardless of primary diagnosis (focal fibrosis acceptable provided it involves \< 20% of BM volume).~* History of pelvic irradiation.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Transplant Patients (Type: EXPERIMENTAL): Patients receiving umbilical cord blood transplantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Pituitary Down-regulation Before IVF for Women With Endometriosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Participant is willing and able to give informed consent for participation in the study.~* Female aged 18 to 39 years old.~* Intending to undergo treatment with a first, second or third cycle of IVF or IVF-ICSI.~* Diagnosed with any degree of endometriosis or endometrioma.~* Participants must meet World Health Organisation Group 1 or 2 eligibility requirements for Combined Oral Contraceptive use.~Exclusion Criteria:~The participant does not understand the English language, or has special communication needs. This is because it is impractical to provide, for this small scale study, information sheets and consent forms in other languages except English.~* The patient has already undergone 3 or more IVF or IVF-ICSI cycles.~* Patients who are already taking any medication to treat endometriosis such as progestins, OCP, Gonadotrophin Releasing Hormone agonists, danazol, mirena, etc. or who have done so within the last 3 months.~* Participants who do not meet World Health Organisation Group 1 or 2 eligibility requirements for Combined Oral Contraceptive use.

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 OCP (Type: EXPERIMENTAL): Combined oral contraceptive pill (OCP) (Microgynon 30) containing Levonorgestrel/Ethinylestradiol 150/30mcg. Taken orally on a continuous regime for 8 weeks, once a day.
- Group 2 Control (Type: NO_INTERVENTION): Control Group - no intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Gastric Accommodation and Gastroesophageal Reflux

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* children and adolescents older than 1-year old who were referred for combined esophageal impedance pH monitoring for GERD\* symptoms~Exclusion Criteria:~* continuous feeding~* previous fundoplication

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Study group (Type: None): Patients with symptoms suggesting gastroesophageal reflux and referred to perform an impedance study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non Metastatic Recurrent Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Rising prostate-specific antigen (PSA) value after local therapy with a PSA doubling time (PSADT) between 6 and 24 months (four or more readings at least two weeks apart within the last six months)~* Prior definitive therapy for prostate cancer consisting of one of the following:~  1. External beam radiotherapy with or without hormone therapy~ 2. Brachytherapy with or without pelvic external beam radiation or hormone therapy~ 3. Radical prostatectomy with or without adjuvant or salvage radiation therapy~* PSA \> 1 ng/ml, which has risen serially on two determinations at least one week apart~* Progressive disease by Phoenix consensus definition for patients who have undergone primary radiation therapy (PSA nadir + 2 ng/mL)~* No metastatic disease~* Prior adjuvant or neoadjuvant androgen deprivation is permitted, provided:~  1. \> 6 months since last day of effective androgen deprivation~ 2. Testosterone \> 250 ng/dL~ 3. Patient is not on intermittent androgen deprivation~* Karnofsky performance status (KPS) of \> 70%~* Liver Function Tests are within normal range~* Glycated hemoglobin (HgA1c) \< 6%~* Patients must be four weeks from major surgery or radiotherapy to be eligible~Exclusion Criteria:~* Presence of another active malignancy other than prostate cancer, or treated squamous/basal cell carcinoma of the skin. Concomitant medical condition which would make it undesirable, in the physician's opinion, for the patient to participate in the protocol or would jeopardize compliance with the protocol requirements~* Diabetes mellitus, unless diet-controlled~* Must be off saw palmetto, pomegranate juice, finasteride, or any herbal agent intended to lower PSA for \> 4 weeks. Baseline PSADT calculation must occur off of these agents~* Patients may not have evidence of local-only recurrence of prostate cancer~* No history of liver disease, including Hepatitis B or C, alcoholic liver disease, or autoimmune liver disease. A prior history of Hepatitis A is allowed provided that baseline liver function tests are within normal limits~* Patients with castration resistant prostate cancer are ineligible (prostate cancer which has progressed on androgen deprivation therapy with a Luteinizing hormone-releasing hormone (LHRH)-agonist or orchiectomy)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Is obese with a BMI ≥35 to ≤45 kg/m2.~* Has stable body weight (not varying by \>5% within 3 months prior to study start).~* Meets certain requirements with respect to concomitant medications.~* Has not smoked or used nicotine-containing products for at least 12 months prior to study start.~Exclusion Criteria:~* Has not been enrolled in a weight loss program within 2 months prior to study start.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): Pramlintide+Metreleptin
- Group B (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~Your child may be eligible for this study if he/she:~* Has received a kidney transplant.~* Has experienced 1 or more episodes of acute rejection or chronic rejection; a rejection episode must have responded to treatment and have occurred at least 30 days before study enrollment.~* Has stable kidney function at the time of study enrollment.~* Is 20 years of age or younger.~* Has written informed consent of parent or guardian if under the age of 18.~* Agrees to use birth control during the study and for 3 months following treatment.~Exclusion Criteria~Your child will not be eligible for this study if he/she:~* Has a history of cancer.~* Has received a multi-organ transplant (more than a kidney).~* Has an active infection.~* Has an abnormal chest X-ray.~* Cannot provide a kidney biopsy at time of study entry.~* Is allergic to sirolimus.~* Has received experimental drugs within 4 weeks of study entry.~* Is pregnant.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Participants will receive SRL, CsA/tacrolimus, and corticosteroids for up to 36 months
- 2 (Type: EXPERIMENTAL): Participants will receive standard CsA or tacrolimus-based double or triple drug therapy for up to 36 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Patients between the ages of 18 to 70 years with Type 2 diabetes who have not been able to adequately control their blood glucose levels~* Note: Only patients who have not been taking any antihyperglycemic medicine for 3 months will be screened~Exclusion Criteria:~* Patients taking any medicines that affect body fluid level such as a diuretic or water pill~* Patients taking niacin or other certain medications~* Patients with any of the following conditions: liver or kidney disease, poorly controlled high blood pressure, heart disease or certain blood disorders~* Patients with abnormal laboratory results from a blood test that will be given before each patient starts the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Part1 - Arm 1 (Type: EXPERIMENTAL): Part1: Arm 1: drug
- Part1 - Arm 2 (Type: PLACEBO_COMPARATOR): Part1 - Arm 2: Pbo comparator
- Part 2 - Arm 1 (Type: PLACEBO_COMPARATOR): Part 2 - Arm 1: Pbo
- Part 2 - Arm 2 (Type: EXPERIMENTAL): Part 2- Arm 2: drug 5mg
- Part 2 - Arm 3 (Type: EXPERIMENTAL): Part 2 - Arm 3: drug 15mg
- Part 2 - Arm 4 (Type: EXPERIMENTAL): Part 2 - Arm 4: drug 30mg
- Part 2 - Arm 5 (Type: ACTIVE_COMPARATOR): Part 2 - Arm 5: active comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Opioid Reduction Initiative During Outpatient Pediatric Urologic Procedures Using Exparel

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pediatric patients 6 years and older undergoing minor pediatric urologic surgery~* Patients who are otherwise eligible to receive routine care following minor urologic surgery~Exclusion Criteria:~* Contraindication to receiving local anesthetics (i.e. pre-existing cardiac, renal, hepatic dysfunction)~* Pediatric patients younger than 6 years of age~* Pediatric patients with a history of pain syndromes or are unable to tolerate opiate medication~* Unwilling to participate in 48 hours and 10-14 day follow-up phone calls

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liposomal Bupivacaine plus 0.25% Bupivacaine (Type: EXPERIMENTAL): Participants will receive local wound infiltration with sequential Liposomal Bupivacaine plus 0.25% Bupivacaine
- 0.25% Bupivacaine alone (Type: ACTIVE_COMPARATOR): Participants will receive local wound infiltration with 0.25% Bupivacaine alone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Calcific Tendonitis Treatment: Barbotage vs. Barbotage With Cortisone Injection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be at least 18 years of age and younger than 90 years of age~* Diagnosed with calcific tendonitis and ruled out other shoulder-related pathologies~* Failed 1st line therapy (physical therapy and cortisone injection)~  * Intention to receive barbotage with cortisone as standard of care~ * 3 or more months of shoulder pain~ * Finding of one or more calcifications ≥5 mm in size on either sonogram or radiograph, located on the supraspinatus tendon~ * Positive Hawkin's test or Neer's sign for impingement~Exclusion Criteria:~* Legally incompetent or mentally impaired (e.g. minors, Alzheimer's subjects, dementia, etc.)~* Osteoarthritis of the glenohumeral joint of the affected shoulder~* Previous surgery or barbotage to the affected shoulder~* History of prior allergic/hypersensitivity reactions related to the study medication~* Shoulder instability, glenohumeral arthritis, AC pathology, inflammatory arthropathy, fibromyalgia, frozen shoulder or cervical radiculopathy~* Sub-acromial injection with a corticosteroid or treatment by ESWT during the last 3 months before inclusion~* Younger than 18 years of age or older than 90~* Any patient considered a vulnerable subject

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Barbotage Injection (Type: EXPERIMENTAL): Subjects receiving barbotage with saline injection
- Barbotage with Cortisone Injection (Type: ACTIVE_COMPARATOR): Subjects receiving barbotage with cortisone injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Pentoxifylline on Rapidly Progressive Glomerulonephritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* biopsied-proved crescentic glomerulonephritis, with rapidly progressive renal failure~Exclusion Criteria:~* Anti-GBM disease, Dialysis-dependency or pulmonary hemorrhage, History of allergy to pentoxifylline, Females are nursing or pregnant, Congestive heart failure, Unstable angina, myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, within the past 6 months prior to signing the informed consent form, Cerebral hemorrhage within the past 6 months prior to signing the informed consent form, Retinal hemorrhage within the past 6 months prior to signing the informed consent form, Known or suspected secondary hypertension, Uncontrolled hypertension or diabetes, Liver cirrhosis or hepatic dysfunction as defined by liver enzymes \> 2 times the upper limit of the normal range, Biliary obstructive disorders, Active malignancy or infection

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- corticosteroids (Type: ACTIVE_COMPARATOR): \[intravenous pulse methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days\] x 3 courses
- pentoxifylline + corticosteroids (Type: EXPERIMENTAL): \[intravenous pulse methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days\] x 3 courses + intravenous infusion of pentoxifylline (0.33-0.66 mg/kg/h) x 7 days + oral pentoxifylline (400-800 mg/day) from days 8 to 90

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Kit for the Prediction of the Risk of Graft Versus Host Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Main inclusion Criteria for Donors :~* Being a relative of the recipient patient, OR being registered on the National Registry of the volunteers for bone marrow donation~* Being candidate for a donation of Hematologic Stem Cells with a HLA compatibility 10/10~Main inclusion Criteria for Recipient :~* Being candidate for a donation of Hematologic Stem Cells with the following criteria:~* HLA compatibility 10/10 with the donor~* Suffering from malignant or non-malignant hemopathy in first remission~* Myeloablative or reducted intensity conditioning~* Classic scheme of immunosuppression decreasing~Main exclusion Criteria:~* Participation to a therapeutical protocol in the 30 last days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Couple donor / recipient (Type: EXPERIMENTAL): Each couple will be treated the same way :~An additional blood sample of the donor will be taken prior GCSF mobilization. This blood sample will then be analyzed via Predictor's kit, by the immunology laboratory of the hospital where the graft will be done.~Whatever the result given by the Predictor' kit, the graft will be done for the recipient patient. No change will be done on the usual graft process.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues